NASDAQ:SBRA • US78573L1061
ChartMill assigns a Buy % Consensus number of 76% to SBRA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-19 | UBS | Maintains | Neutral -> Neutral |
| 2026-02-18 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-02-18 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-17 | Cantor Fitzgerald | Maintains | Neutral -> Neutral |
| 2026-01-20 | Truist Securities | Maintains | Hold -> Hold |
| 2025-11-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-18 | UBS | Initiate | Neutral |
| 2025-10-21 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-01 | Cantor Fitzgerald | Initiate | Neutral |
| 2025-09-03 | Truist Securities | Maintains | Hold -> Hold |
| 2025-08-27 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-25 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2025-08-06 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-23 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-05-12 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-03-18 | Truist Securities | Maintains | Hold -> Hold |
| 2025-02-21 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-17 | Truist Securities | Downgrade | Buy -> Hold |
| 2025-01-07 | JMP Securities | Upgrade | Market Perform -> Market Outperform |
| 2024-12-05 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-10-11 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-09-13 | Citigroup | Upgrade | Neutral -> Buy |
| 2024-09-04 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-26 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-06-27 | Truist Securities | Maintains | Buy -> Buy |
| 2024-05-15 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-01-30 | Deutsche Bank | Initiate | Buy |
| 2024-01-03 | Mizuho | Maintains | Buy -> Buy |
| 2023-11-07 | Stifel | Maintains | Buy -> Buy |
| 2023-10-17 | BMO Capital | Downgrade | Outperform -> Market Perform |
20 analysts have analysed SBRA and the average price target is 21.42 USD. This implies a price increase of 7.48% is expected in the next year compared to the current price of 19.93.
The consensus rating for SABRA HEALTH CARE REIT INC (SBRA) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.